# PCR-RFLP Based Analysis of Functional Polymorphism at MicroRNA-629-Binding Site in the 3'-Untranslated Region of *NBS1* Gene in Prostate Cancer Patients in Local Population



By

Shahzadi Kanwal

99-FBAS/MSBT/S14

Supervisor Dr. Sumbul Khalid Assistant Professor HUI Co-supervisor
Dr. Muhammad Ismail
Director General
IBGE (KRL)

Department of Bioinformatics and Biotechnology
Faculty of Basic and Applied sciences
International Islamic University Islamabad

(2014 - 2016)



MS
616.994


SHP

Carried - Genetic appects

Environmental and-cold

Environmental

Environmental



In the name of Allah, the Most Beneficent, the Most Merciful

#### Department of Bioinformatics and Biotechnology

#### Faculty of Basic and Applied sciences

#### International Islamic University Islamabad

Dated 28-3-16

#### FINAL APPROVAL

It is certificate that we have read the thesis submitted by Ms. Shahzadi kanwal and it is our judgment that this project is of sufficient standard to warrant its acceptance by the International Islamic University. Islamabad for the M.S. Degree in Biotechnology.

#### **COMMITTEE**

External Examiner

Dr. Saima Siddiqi

Senior Scientific Officer,

JBGF KRL, Islamabad

Internal Examiner

Dr. Sobia Tabassum

Assistant Professor, IIUI

Supervisor

Dr Sumbul Khalid

Assistant Professor, HUI

Co-Supervisor

Dr Muhammad Ismail

Director General

IBGF KRL Islamabad

Head of Department

Dr Naveeda Riaz

Chairperson

Department of Bioinformatics and Biotechnology, IIUI

Dean, FBAS

Dr Muhammad Sher

Faculty of Basic and Applied Sciences IIUI

Sur-

- Jones

Missen

· · · · · / · · ·

A thesis submitted to Department of Bioinformatics and Biotechnology,

International Islamic University, Islamabad as a partial

fulfilment of requirement for the award of the

Degree of MS Biotechnology

DEDICATED **TO** MY WORLD'S BEST BELOVED PARENTS & NANA ABU (LATE) GIII G-protein-coupled receptor kinase-interacting protein 1

HR Homologous recombination

HRPC Hormone refractory prostate cancer

IR Ionizing irradiation

KHCO<sub>3</sub> Potassium carbonate

KLK3 Kallikrein-related peptidase 3

KRI Kahuta Research Laboratories

MgCl<sub>2</sub> Magnesium chloride

mRNA Messenger RNA

NBS1 Nijmegen breakage syndrome 1

NH<sub>4</sub>Cl Ammonium chloride

NIII.J Non-homologous end joining

P p-value

Pea Prostate cancer

PCR Polymerase chain reaction

RII P Restriction fragment length polymorphism

RNAi RNA interference

rpm Revolution per minute

rs Reference SNP ID Number

SDS Sodium dodecyl sulphate

SNPs Single nucleotide polymorphism

SPSS Software package Used for Statistical Analysis

SSRNA Single stranded RNA

#### List of Abbreviations

SIL Sodium chloride, tris-HCl and ED [A

TBE Tris borate-ethylene diamine tetra acetic acid

TL Tris EDTA

Thr Threonine

TRBP Transactivation Responsive RNA binding Protein

TRIM33 Tripartite motif-containing 33

UV Ultra violet

Xpo5 Exportin protein

μL Microliter

χ<sup>2</sup> Chι-square vale

DEDICATED
TO
MY
WORLD'S BEST
BELOVED
PARENTS

& NANA ABU (LATE)

### **DECLARATION**

I hereby declare that the work present in the following thesis is my own effort, except where otherwise acknowledged and that the thesis is my own composition. No part of the thesis has been previously presented for any other degree

Date 28-3-16

Shahzadi Kanwal

# **CONTENTS**

ACKNOWLEDGMENTS	I
LIST OF ABBREVIATIONS	111
LIST OF FIGURES	VI
LIST OF TABLES	VII
ABSTRACT	viii
1. INTRODUCTION	1
2. LITERATURE REVIEW	4
2 1 Epidemiology	4
2 2 Androgen receptor Progression model of Pca	6
2 3 Androgen Receptor signaling	8
2.4 Nijmegen breakage syndrome 1	10
2.5 Multiple roles of the MRN complex in DSB repair	11
2 6 Cellular features of NBS	11
2.7 Vital role of NBS1 in homologous recombination	12
2.8 Role of NBS1 in cell-cycle checkpoint control	13
2.9 Role of NBS1 in telomere stability maintenance	13
2.10 Micro RNA	14
INTRODUCTION LITERATURE REVIEW 2 1 Epidemiology 2 2 Androgen receptor Progression model of Pea 2 3 Androgen Receptor signaling 2.4 Nijmegen breakage syndrome 1 2.5 Multiple roles of the MRN complex in DSB repair 2 6 Cellular features of NBS 2.7 Vital role of NBS1 in homologous recombination 2.8 Role of NBS1 in cell-cycle checkpoint control 2.9 Role of NBS1 in telomere stability maintenance	14
2.10.2 MicroRNA genomic location	15
2 10.3 MicroRNA biogenesis	15
2.10.4 MicroRNAs regulation in cancer	18
2.10.5 miRNA profiling in carcinogenesis	18
2.10.6 MicroRNAs as Oncogene	18
2.10.7 MicroRNA as tumor suppressor gene	19

	2.10.8 miRNA mediated suppression of cancer in xenografted mice	21
	2.10.9 Role of MicroRNA 629 in cancer	22
3	MATERIALS AND METHODS	23
	3.1 Subjects	23
	3.2 Blood sample collection	23
	3.3 Identity number allotment	23
	3.4 Extraction of genomic DNA from whole blood samples	23
	3.4.1 Methodology	24
	3.5 Composition of the solutions used in DNA extraction	25
	3.5 1 Cell-lysis buffer	25
	3.5.2 SII buffer	26
	3.5.3 DNA dissolving buffer	26
	3.5.4 SDS solution	26
	3.5.5 Chloroform-isoamyl alcohol	26
	3.6 Assessment of quality and quantity of DNA	27
	3 7 Working solution of DNA	27
	3.8 Reconstitution of primers	27
	3.9 PCR analysis for NBS1 gene	28
	3.9.1 Primers for NBS1 3'UTR	28
	3.9.2 PCR methodology .	28
	3 9.3 Thermal profile of PCR reaction for NBS1 3' UTR	28
	3.9.4 PCR-RFLP of rs14448T>C polymorphism of NBS1 gene	28
	3.9.5 PCR-RTLP of the rs13312986A>G, polymorphism of NBS1 gene	31
	3.10 Analysis of PCR products by using agarose gel electrophoresis	32

3.10.1 Preparation of 10X TBE buffer stock	32
3.10.2 Preparation of 1X TBE buffer stock	32
3.10.3 Preparation of 2 5% agarose gel	32
3.11 Gel electrophoresis and gel documentation	33
3.12 Statistical analysis	33
3.12.1 Hardy-Weinberg Equilibrium	33
3.12.2 Chi square test and p-value	34
4. RESULTS	
4.1 NBS1 3' UTR (rs14448 T>C) genotyping	35
4.2 NBS/ 3' UTR (rs13312986 A>G) genotyping	35
5. DISCUSSION	38
6. REFERENCES	41

#### **ACKNOWLEDGEMENT**

In the name of Allah Almighty, The most gracious and The most merciful The creator, The most supreme Whose mercy enabled me to accomplish this task and bestowed me with success. He blessed me and my parents with resources, audacity and imperturbability. I plead and implore to Allah Almighty that He continues to bless me, my teachers and all human beings. Next to the entire messenger, Hazart Muhammad (Peace Be Upon Him). Who is the internal touch of guidance and knowledge. For the humanity as a whole and is an ever inspiration for all the learned means.

I take this opportunity to thank all those who helped me in this research study. First of all I would like to express my deepest appreciation and most heartfelt gratitude to my supervisor Dr. Sumhul. Khalid. (assistant professor, department of bioinformatics and biotechnology, IIU.I. Islamabad) for her keen interest and persistent encouragement. Despite her busy and tiring schedule she was always there for me and ready to help me in the best probable way. I'm very grateful for her timely help whenever I needed.

My humble gratitude and sincere regards to my co-supervisor Dr. M Ismail (DG, IBGI KRI Islamabad) for giving me opportunity to work in his lab and also for his learned guidance and skilled advice.

Expression sometimes does not reflect the feelings operative behind it, and feelings most of the time do not find words proper for their manifestation. With the deep sense of acknowledgement. I would like to express my humble gratitude to Mr. Ammad Ahmed Farooqi (SSO, IBGE, KRL, Islamabad). Without his help it wouldn't have been possible for me to complete my research study successfully.

I'm highly obliged and grateful to Mr. Qaisar Mansoor (SSO, IBGF KRL Islamabad) for valuable guidance, supervision and opportunity to work under his expertise and benevolently extending all possible facilities for the smooth execution of my research work

I would particularly like to express my profound thanks to Mrs Norcen Qais (technologist at IBGE, KRL, Islamabad), who really extended her helping hand during the course of my research study

Words are inadequate to express my deep sense of indebtedness and gratitude to my friends at Lab 305 especially Amna Zahoor, Rabia Sarwar, Anum Shaukat and Shumaila Akram

for their friendship and generous help Special thanks to all my friends Syeda Saba Shah, Faria Khalid, Ayesha Aftab, Faiza Munir, Huda Shakeel, Samia Atique, Batool Sarfaraz, Samecha Atif, Mehreen Faisal, Misbah Jahangir, Farzana, Iram, Adia Hassan and my students for their valuable friendship and wonderful support

Finally, I can't find words to express my heartiest obligation and thanks to my parents my father (Arshad Mehmood) and my mother (Kausar Parveen), for what I am today is because of them, grand-mother and grand-father (Late), my uncle and aunt (M Waqar Bhatti and Kulsoom Akhter), my brother (Zeeshan Ali), my sisters (Mehmooda Batool and Nida Arshad), my Fiance (M Bilal), my In-Laws and my loving teacher (Ms Rubina Tariq) for their prayers, divine love and moral support to complete this study. I pray to Allah Almighty that, may He bestow me and all mentioned persons with true success in all fields in both worlds and shower His blessed knowledge upon us for the betterment of all Muslims and whole Mankind. Ameen

Shahzadi Kanwal

#### LIST OF ABBREVIATIONS

Acronym Abbreviation

ACD Acid Citrate Dextrose

AIPC Androgen-independent prostate cancer

AR Androgen Receptor

Arg Arginine

A I Ataxia telangiectasia

A I M Ataxia telangiectasia mutation

bp Base pair

°C Degree Celsius

CDK Cyclin-dependent kinase

DBD DNA binding domain

DGCR8 DiGeorge syndrome critical region 8

dH20 Distilled water

DH1 Dihydrotestosterone

DMSO Dimethyl Sulfoxide

DNA Deoxyribonucleic acid

dN1P Deoxyribose nucleotides Triphosphate

DSBs Double-strand breaks

EDIA Ethylene Diamine Tetra Acetic Acid

Fig Figure

FISH Fluorescence in situ hybridization

GIII G-protein-coupled receptor kinase-interacting protein 1

HR Homologous recombination

HRPC Hormone refractory prostate cancer

1R lonizing irradiation

KHCO<sub>3</sub> Potassium carbonate

KI K3 Kallikrein-related peptidase 3

KRI Kahuta Research Laboratories

MgCl<sub>2</sub> Magnesium chloride

mRNA Messenger RNA

NBS1 Nijmegen breakage syndrome 1

NH<sub>4</sub>Cl Ammonium chloride

NHI J Non-homologous end joining

P p-value

Pca Prostate cancer

PCR Polymerase chain reaction

RII P Restriction fragment length polymorphism

RNA interference

rpm Revolution per minute

rs Reference SNP ID Number

SDS Sodium dodecyl sulphate

SNPs Single nucleotide polymorphism

SPSS Software package Used for Statistical Analysis

SINGLE STRANGE STRANGE STRANGE

#### List of Abbreviations

STE Sodium chloride, tris-HCl and EDTA

TBI: Tris borate-ethylene diamine tetra acetic acid

ΓF Tris EDTA

Thr Threonine

IRBP Transactivation Responsive RNA binding Protein

TRIM33 Tripartite motif-containing 33

UV Ultra violet

Xpo5 Exportin protein

μL Microliter

 $\chi^2$  Chi-square vale

# LIST OF FIGURES

Figure No.	Caption	Page No.
2 1	Anatomy of normal and enlarged prostate	5
2 2	Different stages of prostate cancer	5
2 3	Progression to androgen independence in prostate cancer cell	7
2.4	Mechanisms of the androgen action and androgen receptor induced signals in prostate cells	9
2.5	Schematic representation of miRNA biogenesis	17
26	A schematic model showing the molecular mechanisms of microRNA-involved cancer pathogenesis	20
41	PCR-RFLP gel picture for rs14448 T>C genotype	36
4 2	PCR-RFLP gel picture for rs13312986 A>G genotype	37

# LIST OF TABLES

Table No.	Caption	Page No.
31	Sequence of the primers used for the genotyping of NBS1 rs14448T>C	29
3 2	PCR reagents with their concentrations used for PCR	29
3 3	Thermal profile of PCR reaction for NBSI rs14448T>C	30
3.4	Sequence of the primers used for the genotyping of NBS1 rs13312986A>G	31
3 5	Thermal profile of PCR reaction for NBS1 rs13312986A>G	31
41	Analysis of rs14448 T>C genotypes in patients and controls	36
4 2	Analysis of rs13312986 A>G genotypes in patients and controls	37

#### **ABSTRACT**

Prostate cancer is a genomically complex disease and data obtained through laboratory methodologies has considerably improved our understanding of the dysregulation of intracellular signaling cascades. Moreover, microRNAs have also revolutionized our knowledge of cancer biology and it is now known that miRNAs considerably modulate wide ranging target genes. In the present laboratory research, we studied 3' UTR C/T and A/G polymorphism in NBS1 gene in 60 prostate cancer patients and 60 healthy individuals without any previous clinical history, using polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) analysis. For rs13312986 A>G genotypes, AA was 75% in patients and 70% in controls AG was 25% in patients and 30% in controls GG was 0% in patients and none was detected in control. Allelic frequencies for A was 0 875 in patients and 0 85% in controls. Allelic frequencies for G were 0.125% in patients and 0.15% in controls. P value was insignificant for rs13312986 A>G genotypes For rs14448 T>C genotypes, TC was 71 6% in patients and 66 6% in controls TT was 28.3% in patients and 33.33% in controls CC was not detected either in patients or controls T allele was 0.64% in patients and 0.66% in controls. C allele was 0.35% in patients and 0.33% in controls P value was insignificant for rs14448 I>C genotypes Future studies surely will demystify detailed mechanisms, as miRNA regulation of NBS1 is incompletely studied and exploration of these modulations will be helpful in getting a step closer to personalized medicine

Chapter 1 Introduction

#### INTRODUCTION

Prostate cancer (Pca) is a multifaceted and genomically complex disease and research over the decades has gradually shown tremendous breakthroughs in our understanding of the prostate cancer biology. Using high-throughput technologies, it has been shown that overexpression of oncogenes inactivation of tumor suppressor genes, loss of apoptosis, genetic epigenetic mutations dysregulation of Androgen Receptor (AR) mediated intracellular signaling are some of the most extensively studied molecular mechanisms. In-vitro studies have shown that Androgen treatment induced DNA damage in prostate cancer cells.

AR has emerged as one of the most deeply investigated target for prostate cancer therapy. Substantial fraction of information has been added into the existing web of knowledge and increasingly it is being realized that AR has evolved various mechanisms to transduce the signals to downstream effectors in absence or at low levels of androgen. There are some exciting pieces of evidence which shed light on the DNA repair, chromosomal translocations and genomic rearrangements in prostate cancer (Farooqi et al., 2012).

Prostate cancer is one of the most pervasive malignancies around the world constituting a genuine health issue. Clinically localized disease can be successfully treated whereas the disease which is spread throughout an organ or the body remains mostly lethal. Increasingly it is being realized that miRNA plays an important role in deregulation. These are single-stranded, small non-coding, untranslated RNAs which post-transcriptionally modulate wide ranging genes by interacting directly with messenger RNA (mRNA).

Increasingly it is being realized that Pea is the most common diagnosed cancer in men and is the second leading cause of death (Gronberg et al., 2003). Androgen is essential for almost all prostate cancerous cell as well a normal prostate tissues for their survival and growth. Radical prostatectomy or radiation is used to treat localized cancer however. Androgen ablation therapy is suggested for more advance cancers. (Javidan et al., 2005, Deitch et al., 2005).

Substantial fraction of information has been added into existing pool of knowledge that the most protruding participant in the progression of AIPC is the androgen receptor (AR), a protein that binds to androgen and act as a transcription factor to regulate a wide pattern of gene involved in heterogeneous processes including growth and proliferation represented in Fig 1.3 (Chodak et al., 1992. Ruizeveld de Winter et al., 1991, Sadi et al., 1991)

The role of AR in prostate cancer development has been researched in many studies however the precise molecular mechanisms that occur in the development to androgen independence remain largely unexplored and as a result there is no compelling therapies against AIPC (Attar et al., 2009, Debes et al., 2004, Γeldman et al., 2001)

DNA damage consistently over deluge cellular action that response to DNA damage. DNA damage action can develop malignancy due to diminishing the fidelity and efficiency of the DNA repair. NBS1 protein that is integral part of RAD50-MRE11-NBS1 complex (MRN) play crucial role in cellular action to DNA damage and maintain integrity of chromosomes. Nijmegen breakage syndrome (NBS) occur due to mutation in NBS1 gene. NBS is a hereditary recessive genetic disorder which may increase risk of developing malignancy.

It has previously been reported that gene-environment interaction between rs2735383CC genotypic variant and exposure to ionizing radiation (IR) contributed to an increased cancer risk (Yang et al, 2012) rs2735383CC variant genotype carriers had been noted to show an elevated cancer risk when exposed to high or medium level of radiation in an earlier published report (Yang et al, 2012) In accordance with the findings that radiations induced double stranded breaks (DSBs) in human cells and promoted cancer development and progression, it has been assumed that rs2735383CC genotypic variant having lower expression of NBS1 and defective DNA damage repair ability, interaction between rs2735383CC genotypic variant and radiation may increase risk of cancer (Yang et al, 2012)

In Chinese population it has been noted that chromatid breaks were notably higher in X-ray radiation exposed lymphocyte cells from carriers of rs2735383CC homozygote (Yang et al. 2012) It was concluded that rs2735383G>C variation contributed to an increased risk of lung cancer possibly through miR-629 mediated targeting of NBS1 (Yang et al. 2012)

Chapter 1 Introduction

The aims and objectives of the present study are to

✓ To study genetic variation at microRNA-629-binding site in the 3'-untranslated region of \( \begin{align\*} \text{MSI gene} \) in prostate cancer patients

- ✓ There is no previously existing data with reference to germ line mutations and somatic mutations identified in NBSI gene in prostate cancer patients of Pakistani population
- ✓ To probe the genotyping and allelic frequency of NBS1 gene associated with risk of prostate cancer
- ✓ To get further understanding about the genetic basis of prostate cancer

#### Literature Review

Prostate cancer is one of the most pervasive malignancies around the world, constituting a genuine health issue. Clinically localized disease can be successfully treated whereas the disease which is spread throughout an organ or the body remains mostly lethal.

In males, prostrate is an accessory gland and located on the floor of the pelvis and surrounds the neck of urethra and bladder. Normal prostate does not block the flow of urine from the bladder however, enlarged prostate exerts pressure on the bladder and urethra and blocks the flow of urine (see Figure 2.1). Prostate cancer progresses through different stages from stage 0 to stage 4 and is represented in Fig. 2.2.

#### 2.1 Epidemiology

Prostate cancer (Pca) is the second prevailing cancer in males, peculiarly affecting older men over 80% of cases are investigated after age 65. Even though 10% of men with prostate malignancy die of this disease. Therefore in Asian countries the most approbate access to the management of Pca is probably different and consequently individuate Pca screening and treatment strategies on the basis of epidemiological hallmark and socioeconomic status of each country are desired.




Fig 2.1 Anatomy of normal and enlarged prostate (Retrieved from http://www.cancer.gov/images.cdr/live/CDR462221)




Fig 2.2 Different stages of prostate cancer (Retrieved from http://www.cancer.gov/images/cdr/live/CDR442273)

#### 2.2 Androgen receptor: Progression model of Pca

It is intriguing that most of the tumor have become androgen independent but still depend upon the androgen receptor (AR) signaling. Mechanism that upgrade AR signaling in androgen-depleted condition comprise. AR gene amplification, change in the balance of AR cofactor. AR mutation, increase in the steroidogenic precursors and activation through 'outlaw pathways. Numerous other AR-independent "bypass" pathways has been demonstrated to achieve apparently during androgen independence.

MicroRNA concentration and change in the epigenetic impression have also been suspected in the development of androgen independent prostate cancer. Understanding of molecular mechanisms that facade to the development of androgen independent prostate cancer will concede for better and improved therapeutic approach that mark key pathways and molecules that are indispensable for these cell to survive. In spite of very efficient at minimizing cancer growth this treatment hereafter selects for those cells that are no longer susceptible to such therapy resulting in a persist lethal cancer i e androgen-independent prostate cancer (AIPC) (Denmeade et al., 2002, Isaaes et al., 2002)

Cancerous cell has accomplish the ability to grow in the absence of androgen in advance stage of Pca so, hormone therapy is no longer effective and this is the stage at which most patients develop AIPC. Despite androgen independence occurs but most cancers will become androgen independent because these cancerous cell mutate themselves in such a way that enhance their growth in the absence of vital survival factor such as androgens (See fig 2.3). Interestingly, term AIPC is less widely acknowledged because threatening form of cancer still depend upon androgen signaling. However, hormone refractory prostate cancer (HRPC) is becoming more widely acknowledged. (Crawford et al., 2010, Petrylak et al., 2010)




Fig. 2.3: Progression to androgen independence in prostate cancer cells. Different cancer causing forms happen whereby few prostate cells multiply wild (2) Prostate growth cells are at first androgen subordinate along these lines androgen deprivation treatment is effective in pulverizing these disease cells (3) A few cells can survive under this treatment hence keep multiplying (4) Cells are presently androgen autonomous and increase ensuing changes bringing about expanded angiogenesis (5) Androgen-independent prostate cancer (AIPC) starts to metastasize to inaccessible locales (Punit Saraon et al., 2011)

There is a list of exciting findings which has helped us in developing a better understanding of the underlying mechanisms of prostate cancer. It has previously been convincingly revealed that that initial proliferation of prostate cancer cells is androgen dependent and accordingly pharmaceutical inhibition of androgen may be effective against these cancer cells. However androgen exposure induces rewiring of intracellular signaling cascades which make prostate cancer cells resistant against different androgen deprivation therapies.

# 2.3 Androgen Receptor signaling: Important Modulator of Prostate cancer progression

lestosterone is primary androgen produced by the body released by Leydig cells of the testes. In small quantity are also produce in the adrenal glands. Normally, free circulating testosterone is not bound to steroid hormone binding protein. It enters into prostate cells and binds with 5-alpha-reductase, which results in its conversion into a potent metabolite dihydrotestosterone (DΠΓ). DHI binds to AR protein represented in Fig. 2.4. Testosterone itself can bind to the AR but DHI has much more greater potency and have higher affinity. (Radmayr *et al.*, 2008)

AR nuclear accumulation triggers transcriptional regulation of different genes involved in proliferation. AR protein is structurally composed of ligand-binding domain, DNA binding domain (DBD) and amino-terminal domain. Targeting of amino-terminal domain has proved to be an efficient strategy to inhibit activity of the AR (Andersen et al., 2010). Cytosolically located conformational re-organized androgen bound AR gets sequestered from heat shock protein/proteins (HSPs) and enters into the nucleus. AR tethered to DNA sequences through its DNA binding domain. AR regulated different genes which modulate prostate cancer progression and metastasis. Kallikrein-3 encoded by Kallikrein-related peptidase. 3 (KLK3) is a cancer biomarker reportedly modulated by AR.




Fig. 2.4 Mechanisms of the androgen action and androgen receptor induced signals in prostate cells (Radmayr et al., 2008)

#### 2.4 Nijmegen breakage syndrome 1

Nijmegen breakage syndrome (NBS1) the autosomal recessive disorder was first observed in 1981 in the patients who lived in Nijmegen, Holland. Confluence of information suggested that NBS patient's cell have increased level of damage to chromosomes and prone to ionizing irradiation (IR). Increasingly it is being realized that IR caused most dangerous DNA lesions. NBS patients cell are sensitive to all DSB inducing mutagens. NBS1 gene is found to be responsible for Nijmegen breakage syndrome in 1998 (Carney et al., 1998, Matsuura et al., 1998, Varon et al., 1998).

Nibrin is the gene product of NBS1 and contains a 26 kDa fragment (p26-nibrin) the BRC1 and I HA domains complementary to the N-terminal portion of nibrin and a 70 kDa (p70-nibrin) originated by alternatively initiated translation from cryptic upstream start codon (Master et al. 2001)

Nibrin additionally with Rad50 and Mre11 is a part of MRN complex that is trimeric and preserves between mammals and yeast. Confluence of information show that nibrin is phosphorylated at certain sites in response to introduction of double-strand breaks (DSBs). The kinase dependable is the essential initiator of cellular reaction to double-strand break, ataxia telangiectasia mutation (ATM), bi allelic transformation of which prompts ataxia telangiectasia (A1) a huddle with numerous components additionally observe in NBS.

Post-translational modifications of Nibrin are modulated by different enzymes. Ionizing radiation induced phosphorylation of nibrin is further controlled by the deacetylase SIRT1 SIRT1 hypo acetylates nibrin for efficient kinase induced phosphorylation (Yuan *et al.*, 2007)

It is becoming progressively more understandable that nibrin play important role in trigging auto phosphorylation of ataxia telangiectasia mutation (ATM) in response to DNA-damage Deoxyribonucleic acid (DNA) is, simply put, the molecule used to encode all the genetic information required by the living organism to maintain its life functions. Therefore, its stability and integrity is of absolute importance. DNA is actually not a "full-protected" static substance—it is a chemical entity composed of nucleotides attached to a sugar-phosphate backbone. Such a structure can be damaged by environmental factors such as irradiation, chemicals, and ultraviolet rays (UV).

The DNA can also undergo oxidative damage by free radicals, which are byproducts of metabolism. One serious result of these chemical changes in DNA can be double-strand hreaks (DSBs) in the chromosome. Be it environmental or internal, DNA damage must be repaired as the accumulation of unrepaired DNA can lead to aging and disease. Organisms have developed various processes to detect and repair DNA breaks. There are two main double-strand break (DSB) repair pathways, homologous recombination (HR) and non-homologous end joining (NHEJ). One protein complex, the Mre11-Rad50-NBS1 (MRN), has diverse roles in both HR and NHEJ. Each protein component of this versatile complex contributes to the overall structure and functions.

#### 2.5 Multiple roles of the MRN complex in DSB repair

MRN complex may involve at different steps in double-stranded break (DBS) along with DNA end processing, break recognition and cell signaling cascade. And MRN complex that is primary damage sensor may play role in DBS repair in both yeast and human cells. (D. Amours & Jackson et al., 2002) Importance of Rad50-MRE11-NBS1 gene can be observed when any one out of these three genes is disarray resulting in embryonic lethality or cellular non-viability. (Xiao & Weaver et al., 1997. Luo et al., 1999, Zhu et al., 2001). Patient of NBS manifest deficient immune system radiation sensitivity and high risk of malignancy (Shiloh et al., 1997). NBS and A1 (ataxia telangicetasia) both are phenotypically same. (A-T) a related radiation sensitivity disarray (Stewart et al., 1999).

#### 2.6 Cellular features of NBS

Cells illustrate pleiotropic phenotype which are isolated from NBS patients viz the hypersensitivity to ionizing radiation, chromosome impairment, impaired cell cycle checkpoints (Shiloh et al., 1997). Cellular studies have shown that homologous recombination reduced notably in NBS defective cells.

The drift of chromosomal mutation is  $2.5\pm4$  fold elevated in NBS as compare to the normal cells when lymphocytes are exposed to radiations, resulting in chromosomal break. That is similar to ataxia telangicetasia cells and these breaks are tethered to the chromatid type, implying defects in the repair of double-stranded breaks during the S-phase of cell cycle. Furthermore, susceptibility of ionizing radiation of Nijmegen breakage syndrome heterozygotes has not been proved however many attempts are made.

Recently Data obtained through Fluorescence in situ hybridization (FISH) analysis revealed significantly enhanced chromosomal impairment in lymphoblastic cells derived from the NBS heterozygotes. When NBS deficient cells are exposed to ionizing radiation it illustrate abnormal cell cycle regulation although this deformity is limited in nature. And due to radiation unable to conceal their DNA synthesis also intending some deficiency in intra S Phase check points. Furthermore along with deficiency in intra S phase checkpoint control interruption in G1 and G2 checkpoints are also recognized in the NBS cells.

#### 2.7 Vital role of NBS1 in homologous recombination

It is becoming progressively more understandable that NBS1 has a vital role in double-stranded break repair as it coordinate the MRN complex for nuclease action and repair to damage sites. It is intriguing that there are two pathways to rejoin/repair double-stranded breaks viz homologous recombination (HR) and non-homologous end joining (NHEJ). NHEJ has proteins such as DNA-PKes, Ku70/80 and DNA ligase IV and proteins for the HR are RAD51, RAD 52 and RAD 54. It has been observed that these proteins are immensely specific for particular double-stranded break repairing pathway. (Haber et al., 1998)

Increasingly it is being realized that NBS1 functions in homologous recombination (HR) relatively in non-homologous end joining (NHEJ). On the contrary, it is recognized that non-homologous end joining (NHEJ) are tantamount from wild type cells manifesting that NBS1 is not vital for non-homologous end joining (NHEJ). And is sustained by manifestation that V(D)J recombination, less commonly known as somatic recombination which is to be initiated by non-homologous end joining is prevalent in NBS patients (Harfst et al., 2000). MRN Complex is essential for Ig class switch recombination events (Pan et al., 2002. Petersen et al., 2001, van Ingelen et al., 2001).

Data obtained through high throughput technologies has considerably improved our understanding that NBS1 played a vital role in regulation of the V (D) J recombination through suppression of inter chromosomal recombination NBS1 suppresses inter chromosomal homologous recombination (HR) and non-homologous end joining (NHEJ) through MRN complex formation. Deregulation or functional inactivation may cause instability of genome mainly through transfocation as recognized in the NBS cells.

#### 2.8 Role of NBS1 in cell-cycle checkpoint control

Confluence of information suggested that NBS defective cells are radiosensitive and upon treatment with radiomimetic drugs or exposure to ionizing radiation, it show defects in cell cycle check points

Substantial fraction of information has been added into existing pool of knowledge that NBS1 and A1M both are involved in the intra S phase checkpoint controls over the SMC1 phosphorylation

#### 2.9 Role of NBS1 in telomere stability maintenance

Confluence of information show that telomeres are highly functional nucleoprotein structures which maintain the genome integrity by protecting and stabilizing the linear chromosomal ends. Telomeric DNA comprised of tandem array of the 5-26 base pair repetitive sequence of G-rich that align 5' to 3' end and these also assist as the binding sites for various particular telomeric proteins.

Ataxia telangiectasia (AT) is clinically classified as the premature aging syndrome (Metcalfe et al., 1996). Clinically premature aging is not examined in the NBS although NBS patient's blood cell have reduced length of telomeres (Ranganathan et al., 2001). Due to this ahnormal telomeric shortening in the NBS cells, NBSI shows interaction with telomere binding proteins i.e. IRF1 and TRF2 in mammalian telomeres. (Zhu et al., 2000, Wu et al., 2000b). And this interaction can be recognized only at the early S phase of cell cycle where telomeric clongation take place, though MR complex binds to the TRF2 during the whole cell cycle implying that the NBSI play role in telomere replication after the formation of MRN complex like for the DNA repair. (Ranganathan et al., 2001)

Increasingly it is being realized that NBS1 play role in telomere maintenance to accomplish G-strand (telomeric 3' overhang). Hence throughout the cell cycle telomeric fusion take place and telomeric fusion transfer to the decedents due to breakage fusion bridge cycles which leads to the chromosome mutation (Lo et al., 2002).

#### 2.10 Micro RNA

MicroRNAs are a class of small non-coding RNAs usually 10-25 nucleotides that after their processing bind to specific mRNA and degrade it before transcription. They were first discovered in 1993 in non-mammalian species and were characterized to play a pivotal role in development and differentiation in the year 2001. The transcription of miRNAs begins under the supervision of RNA Polymerase II in nucleus that generates a primary miRNA molecule consisting of 5 cap and a poly A tail at 3' end. Most of miRNAs genes are transcribed from the intronic region of DNA and are either transcribed as a single gene or cluster.

This newly synthesized pri-miRNA then undergoes further processing by micro-processing complex consisting of RNAse III enzyme DROSHA and a RNA binding protein DGCR8 (DiGeorge syndrome critical region 8) that trims this molecule in to double stranded pre-miRNA characterized by its hairpin loop structure DROSHA contains two domains for RNAse III that deliberately excises the long structure of Pri-miRNA

This Pre-miRNA is then transported out of the nucleus by the aid of Exportin protein (Xpo5) these protein carry two NLS nuclear localizing sequences that transfer Pre-miRNA out of the nucleus. The energy required for this transportation come Ran GTPase. Upon entering the cytoplasm Pre-miRNA is further processed by another RNAse III enzyme named Dicer1. DICLIR I activity transform Pre-miRNA in to mature miRNA consisting of a leading strand. This mature miRNA is then loaded on to the RNA induced Silencing complex that already carries TRBP (Transactivation Responsive RNA binding Protein and AGO (Argonaut proteins). There are different views about the mechanism of action of TRBP and AGO, most appraisal view suggests that TRBPs aid in physiological binding of different types of AGO proteins with DICLIR. This activity in turns promote guiding strand to bind to the target mRNAs in the presence of GW 18 proteins and gene silencing of targeted mRNAs.

#### 2.10.1 History of miRNA

Lee et al in 1993, recognized that the lin-4 gene is interpreted into the ~ 22 nucleotide long RNA which inhibits the lin-14 gene through RNA interference (RNA1) in Caenor habditis elegans (nematode). It is also concluded that the lin-4 gene may associate with the regulatory, small non-translated RNA. I et-7, second microRNA in Caenorhabditis elegans. Drosophila and human was recognized in the 2000 (Reinhart et al., 2000).

Moreover with discovery of ~22 nucleotide RNAs in 2001(Lagos-Quintana et al 2001) lee and Ambros et al , 2001, Lau et al , 2001) named them as microRNAs (miRNAs)

It is interesting to note that in human genome ~1000 miRNAs are predicted to exist (Berezikov et al., 2005) Sanger miRBase (the microRNA database) was created to administer the database of microRNA sequence and regulate nomenclature in 2006 (Griffiths-jones et al., 2006). It is intriguing that in March 2011, about 1037 human microRNA were commentate at the miRBase.

#### 2.10.2 MicroRNA genomic location

It is intriguing that many microRNAs are positioned in noticeable regions that are far from the protein coding genes (Lee et al., 2001, Ambros et al., 2001). These microRNA genes are assert from their own promoter. In addition ~40% of the microRNA are positioned in introns of the protein coding genes, generally with equivalent orientation same as host genes (Rodriguez et al., 2004). Moreover some microRNAs are positioned far from the other microRNA loci, while other are positioned adjacent to one another and considered to be elucidate in the clusters (Altuvia et al., 2005). MiRBase (the microRNA database) elucidate cluster as group of microRNAs that are positioned not beyond 10kb (kilo base) pair of each other.

#### 2.10.3 MicroRNA biogenesis

Confluence of information suggest that several investigators have been efficiently reviewed microRNA biogenesis (Bartel et al., 2004, Chen et al., 2005, Kim et al., 2005, Tomari and Zamore et al., 2005). Briefly, miRNA is produced by RNA polymerase II and it is termed as primary-miRNA (pri miRNA) and the process is endogenous (inside the cell). Primary mi-RNA form distinct hairpin shaped, stem looped secondary structures containing an enzyme named. Drosha (a RNAase III endonuclease) and fundamental cofactor DGCR8/Pasha.

Drosha and DGCR8 combine together and act on the pri-miRNA and cut some region of pri-miRNA and make it shorter and is termed as pre-miRNA ~60-70 nucleotide long. This pre-miRNA enters into cytoplasm with the help of protein 1. e Exportin 5 (Exp. 5) member of Ran transport receptor family). So once this pre-miRNA enter into the cytoplasm this will undergo further stages of dicing 1. e cleavage after this dicer act on this pre-miRNA and activate it properly

Chapter 2 Literature Review

Dicer is an RNAase III type of enzyme it is double-stranded RNA (dsRNA) specific endonuclease. Dicer will bind with this pre-miRNA and cleave it and results in 3, overhang of 2 nucleotide and 5, monophosphate region and this complex is termed as miRNA miRNA\* duplex ~15-20 nucleotide long.

Finally miRNA miRNA\* duplex is unwounded to produce mature miRNA and miRNA\* with the help of helicase. And then this mature miRNA is incorporated into a RISC (RNA induces silencing complex).

RISC is consisting of protein slicer and Argonaut (AGO 1-4) then this mature miRNA binds with RISC complex and facilitates gene silencing via binding to 3' untranslated region UTR sequences which are complementary to the miRNA sequence. (Meister  $et\ al$ , 2004) Then RISC complex along with guide strand 1. e.  $\sim$  2-8 nucleotide long will migrate to the actual targeted sequence of single stranded RNA (ssRNA) leading to the translation inhibition or degradation of mRNA target represented in Fig 2.5

Chapter 2 Literature Review




Fig 2.5 Schematic representation of miRNA biogenesis (Farooqi et al., 2012)

Chapter 2 Literature Review

## 2.10.4 MicroRNAs regulation in cancer

It is intriguing that loss of apoptosis and abnormal growth lead to malignancy or cancer formation in the cell. It is becoming progressively more understandable that microRNA involve in regulation of apoptosis and cell growth. MicroRNA function in many pathological and biological processes lead to malignancy initiation, progression and metastasis formation. MicroRNA regulate gene control in DNA damage repair DDR and its entanglement in malignancy progression will help in understanding the impact of these small molecules in the DNA damage or repair as well as chemo and radio-resistance mechanism.

Furthermore studies acknowledge both upregulation and downregulation of microRNA in all substantial tumor and the leukemia. Interestingly, while some microRNAs seem to have a tissue-specific function and are only expressed in specific cancers, others are universally over expressed or under expressed in cancer. (Chan et al., 2005, Iorio et al., 2005, Volinia et al., 2006)

### 2.10.5 miRNA profiling in carcinogenesis

It is intriguing that microRNAs mediated all the hallmarks of malignancy including apoptosis, tissue invasion, uncontrolled replicative ability, metastasis and sustained angiogenesis (Hanhan and Weinber et al., 2011). MicroRNA can act both as oncogenes or tumor suppressor gone depending upon their target. MicroRNA has highly complex regulatory machinery as one messenger RNA can be targeted by the multiple microRNAs. Confluence of information suggest that microRNAs take on hundreds of targets synchronously as these are the tempting targets for therapy of cancer. It is interestingly to noted that miRNA play role in tumorigenesis so it's become attractive target for novel therapies either in combination with the chemotherapeutical agents or may be alone.

# 2.10.6 MicroRNAs as Oncogene

Confluence of information clearly suggest miRNA mediate targeting of tumor suppressor genes. There is an overwhelmingly increasing list of the target reported to be quantitatively controlled by oncogenic miRNA. In tumor when miRNA showed increased expression is considered as oncogenes/ oncomirs, involve in tumor progression by negatively inhibition of the tumor suppressor genes.

Good example of an oncogenic microRNA is mir-17-92 and is located at the chromosome 13q31 the genomic locus that is exaggerate in different types of lymphoma and lung cancer also including diffuse large B cell lymphoma (Hayashita *et al.*, 2005, He *et al.*, 2005b)

It is intriguing that mir-17-92 involve in lung cancer and increase risk of lung cancer cell growth (Hayashita et al., 2005). Substantial fraction of information has been added into existing pool of knowledge that miR-17-92 is associated with the c-Myc (Avian myelocytomatosis virus oncogene cellular homolog) gene expression. C-Myc is known to be as best characterized oncogene and both c-Myc and miR-17-92 are associated with the expression of the cell cycle transcription factor gene E2F1 (E2F Transcription Factor 1) is a Protein Coding gene (O'Donnell et al., 2005). Confluence of information show that if c-Myc gene is not properly expressed and show dysfunction it may lead to human cancer (Cole and McMahon et al., 1999).

Other oncogenic microRNAs are miR-373 and miR-372 reportedly involved in regulation of cancer as oncogenes in the human testicular germ cell tumor. And these two oncogenic miRNAs are associated with the increase tumor development and cell proliferation by overcoming p53-mediated CDK (Cyclin-dependent kinase) inhibition or may possibly by direct inhibition of LATS2 expression (tumor suppressor gene) (Voorhoeve et al., 2006)

# 2.10.7 MicroRNA as tumor suppressor gene

Increasingly it is being realized that miR let-7 may highly maintain including worm to human being (Pasquinelli et al., 2000), and may also associated with the developmental stages and timings (Johnson et al., 2003, Johnston and Hobert et al., 2003, Miska et al., 2004. Thomson et al., 2004) Decreased levels of miR let-7 are investigated during early developmental stages of the animal and in differentiated adult tissues there are increased levels of miR-let-7 expression has been observed (Miska et al., 2004, Thomson et al., 2004). It is intriguing that if miR let-7 express inappropriately it leads to oncogenic loss of differentiation (Reinhart et al., 2000).

Recent studies reveals that miR let-7 directly targets RAS oncogene by its negative regulation result in repression of translation (Johnson et al., 2005). It is interestingly noted that there is decreased level of the miR let-7 and increased level of RAS protein in lung tumor tissues rather than the normal tissues implying that negative regulation of RAS by miR let-7 is a tool for miR let-7 to function as a tumor suppressor gene in ease of lung oncogenesis represented in Fig. 2.6 (Johnson et al., 2005).




Fig 2.6 A schematic model showing the molecular mechanisms of microRNA-involved cancer pathogenesis (Baohong Zhang et al., 2006)

## 2.10.8 miRNA mediated suppression of cancer in xenografted mice

Increasingly it is being realized that activation of pro-survival signaling in cancer cells induces resistance against chemotherapeutic drugs. Interestingly, there is tremendously accumulating experimental evidence of targeting of key proteins of pro-survival signaling using different strategies. It has lately been shown that ectopic expression of miR-506 in lung cancer cells considerably repressed NFKB (Yin et al., 2014).

Growing body of evidence substantiates the fact that upregulated expression of hIERT is associated with the growth and metastasis of gastric tumor. Intriguingly, miR-1207-5p and miR-1266 remarkably inhibited tumor formation in mice (Chen et al., 2014).

It has recently been convincingly revealed that over-expression of miR181b in metastatic breast cancer cells notably repressed metastasis formation in immunodeficient mice miR-181b negatively regulated CXCL1 and -2 as evidenced by in-vitro analysis of curcumin treated cancer cells (Kronski et al., 2014)

miR-520c-3p mediated control of translation initiation factor, eIF4GII is also noted to play an essential role. Inoculating, miR-520c-3p overexpressing cancer cells in mice notably inhibited tumor formation (Mazan-Mamezarz *et al.*, 2014).

miR-656 is also a tumor suppressor reported to exert its inhibitory effects on glioma cell proliferation via negative regulation of Bone morphogenetic protein 2. There is a direct piece of evidence suggesting that non-canonical BMP/MAPK and canonical BMP/Smad pathways were inhibited in miR-656 overexpressing cancer cells. Moreover, ectopic expression of miR-656 induced regression of tumor in mice (Guo et al., 2014)

Confluence of information suggested that downregulation of miR-193a-3p/5p induced lymph node metastasis and tumor node metastasis. Overexpressing miR-193a-3p/5p in Non-Small Cell Lung Cancer Cells considerably repressed proliferation and migration. Detailed mechanistic insights highlighted that miR-193a-3p/5p exerted its growth inhibitory effects via negative regulation of ERBB4 and S6K2 (Yu et al., 2015).

miRNA mediated inhibitory effects on angiogenesis are also being studied. Concordant with this notion, a recent study provided compelling evidence that introducing miR-542-3p in tumor-bearing mice induced regression of tumor, angiogenesis, and metastasis (He et al., 2014).

G-protein-coupled receptor kinase-interacting protein 1 (GIT1) is involved in regulation of Oral Squamous Cell Carcinoma Invasion. In-vivo study revealed that injecting GIT1-siRNA expressing C9-lung-IV2 cells into SCID mice significantly reduced lung metastasis. It was experimentally verified that expression of miR-491-5p resulted in substantially reduced targeting of C9-lung-IV2 cells to lung 24 hours after injection (Huang et al., 2014).

### 2.10.9 Role of MicroRNA 629 in cancer

miR-629 was reported to be significantly higher in gastric cancer patients as compared to controls (Shin et al. 2015). Viral E6 and E7 oncoproteins are essential for induction of transformation and maintenance of the tumorigenic phenotype of HPV-infected cervical cancer cells. It has been convincingly revealed that higher intracellular levels of miR-629-5p are noted in E6/E7 expressing cervical cancer cells (Honegger et al., 2015).

miR-629 has been shown to modulate different genes. Tripartite motif-containing 33 (TRIM33) is reportedly targeted by miR-629 that consequently inhibits TGFβ/Smad signaling cascade. In clinical ccRCC specimens, downregulated TRIM33 levels associated notably with pathologic stages and grades. Detailed mechanistic insights revealed that TGFβ-induced/Smad activation was significantly suppressed in cancer cells treated with miR-629 inhibitor. TRIM33 level was considerably enhanced in miR-629 inhibitor treated cancer cells and there was markedly reduced structural association of Smad4 with Smad2/3. TGFβ treatment induced an upregulation of expression levels of EMT-related factors in miR-629 mimic transfected renal cell carcinoma cells (Jingushi et al., 2015)

## MATERIALS AND METHODS

## 3.1 Subjects

Prostate cancer patient's blood samples using informed consent were provided by KRI Hospital Islamabad along with the clinical evaluation and diagnosis. The present study was conducted in the institute of Biomedical and Genetic Engineering (IBGE), Islamabad

## 3.2 Blood sample collection

The patients were assessed by personal information and clinical investigations all information was included in a clinical questionnaire. The patients were informed about the objectives of the study and consent form was signed by every participant. 5ml blood was drawn from each participant and collected in Acid Citrate Dextrose (ACD) vacutainer (BD Franklin Lakes NJ USA) which contained 2.5ml acid-citrate-dextrose solution, the final volume was 7.5ml. This ACD vacutainer serve as preservative and anticoagulant for the fresh blood sample. The vacutainer tubes were inverted few times immediately and stored at 4°C till further processing.

# 3.3 Identity number allotment

All the samples were assigned specific identity numbers as PCA-001 PCA-002 and so on Moreover an individual taken as controls were also given i d as CPCA-001, CPCA-002 and so on

# 3.4 Extraction of genomic DNA from whole blood samples

The genomic DNA from all of the samples was isolated by following standard organic method which recruits two chief organic chemicals namely Phenol and Chloroform (Sambrook and Russell 2001). The protocol was slightly modified as per requirement.

The DNA extraction was performed in strict accordance to the following steps

### 3.4.1 Methodology

DNA extraction procedure was completed in three days. The detail of the procedure is as follow

#### Day 1

- 1 The samples were transferred to 50ml falcon tubes and 3X volume of cell lysis buffer (KHCO3, NH4Cl and 0.5M EDTA) was added. Tubes were placed on ice for 30 min
- 2 Then the samples were centrifuged at 1200rpm for 10 minutes at 4°C in refrigerated centrifuge (Eppendorf Refrigerated Centrifuge 5130)
- 3 The supernatant was discarded and the pellet at the base of the tube was re-suspended
- 4 If the pellet was reddish then again 10ml of cell lysis buffer was added. The sample tubes were centrifuged at 1200rpm at 4°C for 10 minutes.
- 5 The supernatant was discarded and the pellet was re-suspended
- 6 To the pellet, 4.75ml of STE (Sodium Chloride, Tris-HCl, and EDTA) and 250μl of 10% SDS (sodium dodecyl sulfate) were added
- 7 To the above mixture 10µL of proteinase K enzyme (20mg/ml) (Fermentas, Lithuania) was added and samples were incubated at 55°C for overnight in shaking water bath (Orbit Shaker Bath, Lab-Line, USA)

#### Day 2

- 8 The samples were extracted with 5ml (equal quantity) of equilibrated phenol (pH=8) agitated for 10 minutes and kept on ice for 10 minutes. Spun at 3200rpm for 30 min at 4°C in refrigerated centrifuge (Eppendorf Refrigerated Centrifuge 5130), removed the supernatant with 1ml cut tip into the separate labeled 15ml centrifuge tubes.
- 9 To the samples 5ml of chilled chloroform isoamyl alcohol (24.1) was added and agitated for 10 minutes and kept on ice for 10 minutes. Samples were spun at 3200rpm

for 30 minutes at 4°C in refrigerated centrifuge (Eppendorf Refrigerated Centrifuge 5130). The supernatant was separated with cut tip into the separate labeled 15ml centrifuge tubes.

10 To the isolated supernatant added 500μL of 10M ammonium acetate and 5ml of chilled Isopropanol and agitated until DNA precipitates as visible white threads. The samples were then placed overnight at -20°C (or for 15 minutes at -70°C)

### Day 3:

- 11 The samples were then centrifuged at 3000rpm for 60 minutes at 4°C in refrigerated centrifuge (Eppendorf Refrigerated Centrifuge 5130). The supernatant was discarded and the DNA pellet was loosened by tapping the 15ml centrifuge tube.
- 12 Then the loosened DNA pellet was washed with 5ml of chilled 70% ethanol 3200rpm for 40 minutes at 4°C in refrigerated centrifuge (Eppendorf Refrigerated Centrifuge 5130)
- 13 The supernatant was discarded and the DNA pellet was dried
- 14 The dried pellet was dissolved in TE (10mM Tris, 1mM EDTA) buffer (the volume buffer added according to the size of the pellet)
- 15 The complete DNA dissolving in TE buffer was achieved by incubating the sample tube in shaking water bath at 55°C (Orbit Shaker Bath, Lab-Linc, USA)
- 16 The DNA samples were then transferred to 1.5 ml labelled Eppendorf tubes and stored at 4°C

# 3.5 Composition of the solutions used in DNA extraction

#### 3.5.1 Cell-lysis buffer

Į

This buffer is composed of three chemicals as

KHCO3 (Potassium Carbonate) 1gm/L

- 11 NH4Cl (Ammonium Chloride) 8 29gm/L
- m 0 5 M ED l'A (Ethylene Diamine Tetra Acetate) 0 34gm

Cell lysis buffer cleaves the cell membranes and exposes the chromatin material of the nucleated cells

#### 3.5.2 STE buffer

This buffer provides a saline environment to the newly exposed chromatin material

- 3M NaCl (Sodium Chloride) 33 3ml
- IM Tris-HCl buffer (pH8 0) 4 0ml
- 111 0 5M EDTA (pH8 0) 2 0ml

The above reagents were mixed and volume was made up to 1 liter with dH2O

### 3.5.3 DNA dissolving buffer

This buffer is used for dissolving the DNA and is composed of

- 1 10mM Tris-HCI (pH8 0)
- 11 0 1mM EDTA

#### 3.5.4 SDS solution

10 % solution of sodium dodecyl sulfate or sodium lauryl sulfate helps in protein degradation

#### 3.5.5 Chloroform-isoamyl alcohol

This solution is made in 24.1 v/v for 500ml total volume as

- Chloroform 480ml (24)
- u Jsoamyl alcohol 20ml (1)

## 3.6 Assessment of quality and quantity of DNA

The Optical density (OD) of DNA samples were measured at 260nm and 280nm by Spectrophotometer (Bio-Rad Laboratories, USA) Optical density (OD) ratio for each sample was calculated as

OD = Absorbance at 260nm / Absorbance at 280nm

The quality of genomic DNA was determined by taking ratio of ODs at these two wavelengths (260/280). The ratio ranges between 1.7-1.9 was considered best. If the ratio comes out to be greater than 1.9 then it may have phenolic contamination and the ratio below 1.7 is considered to have proteinic contamination. Those samples having ODs out of this range (1.7-1.9) were resuspended for the second time and their ODs were calculated again.

Quantification was done using formula

Abs 260nm\*50=DNA concentration (µg/ml)

## 3.7 Working solution of DNA

 $25 ng/\mu I$  working solution of DNA was prepared from the stock DNA solution by using the following ratio

DNA stock dH2O

60μL 140 μJ

# 3.8 Reconstitution of primers

Lyophilized primers were mixed with calculated amount of deionized water to make a stock solution of 100  $\mu$ M of each primer. From these 100 $\mu$ M stock primer solutions, 20 $\mu$ M working solutions for each primer were prepared by taking 20 $\mu$ I stock solution and 80 $\mu$ I of distilled water. PCR amplifications were performed by using 20 $\mu$ M primer solutions.

## 3.9 PCR analysis for NBS1 gene

Polymerase chain reaction was carried out to amplify the NBS1 gene in which polymorphism was present

#### 3.9.1 Primers for NBS1 3'UTR

In order to determine 3'UTR polymorphism in the *NBS1* gene PCR was performed by the following primers designed for the analysis. Details of primers are given in table 3.1

### 3.9.2 PCR methodology

After optimization with reproducible results, all samples were amplified at optimized conditions of PCR. The master mix for all PCR reactions with specific primer pair was prepared in 1 5mL Eppendorf tube. Total reaction volume for a single PCR reaction was 25µL. All the PCR reagents with their concentrations are summarized in the table 3.2.

### 3.9.3 Thermal profile of PCR reaction for NBS1 3' UTR

The above PCR was carried out in 96 well thermal cycler (Thermo I lectron Corporation Mill ford, USA) at the following thermal stages, steps and cycles as shown in table 3.3

#### 3.9.4 PCR-RFLP of rs14448T>C polymorphism of NBS1 gene

For NBS1 genotyping the amplified DNA fragments harboring the SNP were digested with Rval restriction enzyme. Digestion was performed on all samples by adding 1µL Rval enzymes, 3µL of digestion buffer for NBS1 adjusted with dH2O for final volume of 20µL of PCR reaction mixture. It was mixed gently and spins down for few seconds. The reaction mixture was incubated at 37°C for 16 hours. The RFLP products were checked on 2.5% agarose gel containing ethidium bromide. The agarose gel electrophoresis was done at 200 volts for 30 minutes using Bio-Rad Power PAC 3000.

Table 3 1: Sequence of the primers used for the genotyping of NBS1 rs14448T>C

Regions	Primer	Sequence
NBS1	Forward primer	5'GCAGAGACCTGTGGGAAGCGA 3
3'UTR	Reverse primer	5' ACCGTAGCTGCCCTGGTAGGT 3

Table 3.2: PCR reagents with their concentrations used for PCR

Sr. No.	Reagents with initial concentration.	Volume used	Total volume for	
		(µl)	100 reactions	
1	d H2O	10 8 µl	1080 μΙ	
2	10x PCR buffer (Fermentas, Lithuania)	2 5 μΙ	250 µl	
3	MgCl2 (Fermentas, Lithuania)	Ι 5 μΙ	150 μΙ	
4	2 0 mM dNTPs	1 0 μ1	100 μ1	
5	5U/μl Γaq DNA polymerase (Fermentas, Lithuania)	0 2 µI	20 µl	
6	10 μM Γorward primer	1 μ!	100 µ1	
7	10 μM Reverse primer	tμl	100 μΙ	
8	25 ng Sample Genomic DNA	5 μΙ	5 μΙ	
9	Triton/Glycerol	20 µI	200 μl	

Table 3 3: Thermal profile of PCR reaction for NBS1 rs14448T>C

No. of Stage	No. of Step	Temperature	Time	No. of Cycles
Stage 1	Step 1	95 °C	4 Minutes	01 Cycle
Stage 2	Step 1	95 °C	45 Seconds	35 Cycles
	Step 2	60 °C	45 Seconds	
	Step 3	72 °C	45 Seconds	
Stage 3	Step 1	72 °C	10 Minutes	01 Cycle

### 3.9.5 PCR-RFLP of the rs13312986A>G, polymorphism of NBS1 gene

For NBSI genotyping the amplified DNA fragments harboring the SNP were digested with Alul restriction enzyme. Digestion was performed on all samples by adding 1µI Alul enzymes, 3µL of digestion buffer for NBSI adjusted with dH2O for final volume of 20µL of PCR reaction mixture. It was mixed gently and spins down for few seconds. The reaction mixture was incubated at 37°C for 16 hours. The RFLP products were checked on 2.5% agarose gel containing ethidium bromide. The agarose gel electrophoresis was done at 200 volts for 30 minutes using Bio-Rad Power PAC 3000.

Table 3.4: Sequence of the primers used for the genotyping of NBSI rs13312986A>G

Regions	Primer	Sequence
NBSI	Forward primer	5'GCAGAGACCTGTGGGAAGCGA 3
3'UTR	Reverse primer	5' ACCGTAGCTGCCCTGGTAGG1 3'

Table 3 5: Thermal profile of PCR reaction for NBSI rs13312986A>G

No. of Stage	No. of Step	Temperature	Time	No. of Cycles
Stage 1	Step 1	94 °C	5 Minutes	01 Cycle
Stage 2	Step 1	94 °C	45 Seconds	35 Cycles
	Step 2	55 °C	45 Seconds	
	Step 3	72 °C	45 Seconds	_
Stage 3	Step 1	72 °C	10 Minutes	01 Cycle

# 3.10 Analysis of PCR products by using agarose gel electrophoresis

Analysis of PCR product was performed by using agarose gel electrophoresis

I ollowing reagents were used in the process of agarose gel electrophoresis

- a) 10x TBE buffer (Iris-Borate- Ethylene diamine tetra acetic acid)
- b) 6X Gel loading dye (Fermentas, Lithuania)
- c) 10mg/ml Fthidium Bromide
- d) 2% Agarose (Promega)
- c) 100bp DNA Ladder (Ferments Lithuania)

## 3.10.1 Preparation of 10X TBE buffer stock

- 1 Tris-base (promega) = 107 8gm/liter
- n Boric acid (promega) = 55 02gm/liter
- III ED  $\Gamma$ A (Ethylene diamine tetra acetic acid) (Bio Rad) = 9.04gm/liter

All reagents were dissolved in 800ml deionized water using magnetic stirrer and finally 1000ml volume was made in measuring cylinder and stirred to mix well

### 3.10.2 Preparation of 1X TBE buffer stock

```
10X \text{ TBE buffer} = 200\text{mL}
```

dH2O = 1800mL

#### 3.10.3 Preparation of 2.5% agarose gel

For 20cm \20cm agarose gel pouring plate 300 ml of 2 5% agarose was made as

1 Ion free fine agarose (Promega) = 6 5gm

 $\mu 1X TBE = 300mI$ 

III Glycerin =  $300\mu$ I

iv Lthidium bromide  $(10\text{mg/ml}) = 5\mu l$ 

Mix 6 5gm agarose, 300ml 1X TBE and 300µl glycerin in Pyrex bottle and heat in oven with loose bottle cap until agarose boils to mix in liquids. Add 5µl Ethidium bromide in the agarose gel solution and shake to mix. Set the 20cm×20cm gel plate with combs at suitable distance and pour the gel solution. The gel was polymerized in 30-45 minutes.

## 3.11 Gel electrophoresis and gel documentation

Before loading the sample in the gel, 5µl of the PCR product was mixed with 6X gcl loading buffer (I ermentas, Lituania). Then samples were loaded on agarose gel. In the first well of gel. 100bp DNA marker was loaded as size reference for amplified target DNA. The gel was run for 35 minutes using the Maxicell EC360-M electrophoretic gel system (EC Apparatus Corporation. St. Petersburg, Florida, USA) at 200 constant volts by using BioRad Power Pack 3000 (BioRad, USA) in 1X TBE buffer. DNA bands were visualized under UV illumination and photographed using Syngene gel documentation system (Gene Genius, Syngene, UK).

# 3.12 Statistical analysis

The following statistical tests were performed for the data

## 3.12.1 Hardy-Weinberg Equilibrium

The frequency of NBS1 SNP was calculated by Hardy- Weinberg Equilibrium equation

$$p^2 + 2pq + q^2 = I$$

The allele frequency of the study groups was calculated by using the following formula

Allele Frequency = No of that allele in study group

Total no of allele

### 3.12.2 Chi square test and p-value

To find the association of the NBS1 gene with the prostate patients the p value and Chi square test was performed by using statistical program SPSS (Version 20.0) and as described by Preacher (Preacher, 2001) A p-value < 0.05 was considered as statistically significant whereas p value > 0.05 was taken as non-significant

## RESULTS

In the present laboratory research, we studied 3' UTR C/T and A/G polymorphism in NBS1 gene in 60 prostate cancer patients and 60 healthy individuals without any previous clinical history, using polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) analysis. For rs13312986 A>G genotypes, AA was 75% in patients and 70% in controls. AG was 25% in patients and 30% in controls. GG was 0% in patients and none was detected in control. Allelic frequencies for A was 0.875 in patients and 0.85% in controls. Allelic frequencies for G were 0.125% in patients and 0.15% in controls. P value was insignificant for rs13312986 A>G genotypes. For rs14448 T>C genotypes, TC was 71.6% in patients and 66.6% in controls. I I was 28.3% in patients and 33.33% in controls. CC was not detected either in patients or controls. T allele was 0.64% in patients and 0.66% in controls. C allele was 0.35% in patients and 0.33% in controls. P value was insignificant for rs14448 T>C genotypes.

# 4.1 NBS1 3' UTR (rs14448 T>C) genotyping

For rs14448 I>C genotypes, TC was 71 6% in patients and 66 6% in controls T1 was 28 3% in patients and 33 33% in controls CC was not detected either in patients or controls T allele was 0.64% in patients and 0.66% in controls C allele was 0.35% in patients and 0.33% in controls P value was insignificant for rs14448 T>C genotypes. As shown in Fig. 4.1 and Table 4.1

# 4.2 NBS1 3' UTR (rs13312986 A>G) genotyping

For rs13312986 A>G genotypes, AA was 75% in patients and 70% in controls AG was 25% in patients and 30% in controls GG was 0% in patients and none was detected in control Allelic frequencies for A was 0.875 in patients and 0.85% in controls Allelic frequencies for G were 0.125% in patients and 0.15% in controls P value was insignificant for rs13312986 A>G genotypes As shown in Fig 4.2 and Table 4.2




Fig 4.1: For rs14448 T>C, TT is 168 bp, TC is 168, 146, 22bp and CC is146, 22bp Lane 1 is ladder, Lane 2-12 is TC and Lane 13 is TT.

Table 4.1: Analysis of rs14448 T>C genotypes in patients and controls

Study Group	rs14448 T>C genotypes (Percentage)			Allele Frequencies	
Отопр	TC	TT	CC	T	С
Patients (n=60)	43 (71.6)	17 (28.33)	0	0 64	0.35
Control (n=60)	40 (66.66)	20 (33.33)	0	0.66	0.33
<i>p</i> -value	0.67	0.524	1	ı	0.974




Fig 4.2: For rs13312986 A>G genotypes, AA is 170, 50 bp. AG is 220, 170, 50bp and GG is 220 bp. Lane 1 is ladder. Lane 2-8 is AG, Lane 9 is AA.

Table 4.2: Analysis of rs13312986 A>G genotypes in patients and controls

Study Group	rs13312986 A>G genotypes			Allele Frequencies	
	AA	AG	GG	A	G
Patients	45	15	0	0.875	0 125
(n=60)	(75%)	(25%)	v	0.075	0.125
Control	42	18	0	0.85	0 15
(n=60)	(70%)	(30%)	U	0.85	013
p-value	0.67	0.499	I	1	0 964

Chapter 5 Discussion

### DISCUSSION

Prostate cancer (Pea) is a multifaceted and genomically complex disease and research over the decades has gradually shown tremendous breakthroughs in our understanding of the prostate cancer biology. Prostate cancer is one of the most pervasive malignancies around the world constituting a genuine health issue. Clinically localized disease can be successfully treated whereas the disease which is spread throughout an organ or the body remains mostly lethal. Increasingly it is being realized that miRNA plays an important role in deregulation. Increasingly it is being realized that Pea is the most common diagnosed cancer in men and is the second leading cause of death (Gronberg et al., 2003).

Androgen receptor (AR) has emerged as one of the most deeply investigated target for prostate cancer therapy. It is intriguing that AR has emerged as one of the most deeply investigated target for prostate cancer therapy. The role of AR in prostate cancer development has been researched in many studies, however the precise molecular mechanisms that occur in the development to androgen independence remain largely unexplored and as a result there is no compelling therapies against AIPC (Attar et al., 2009, Debes et al., 2004, Feldman et al., 2001).

It has been reported that *NBS1* gene polymorphism might affect function of gene and may lead to cancer susceptibility. We hypothesized that *NBS1* gene polymorphism is associated with the risk of lung cancer. Two independent case-control studies was conducted in Southern and Eastern Chinese population. From these studies it is concluded that there was no significant association found for tag SNP's rs13312986 and rs14448 whereas rs2735383CC variant genotype carriers had been noted to show an elevated cancer risk when exposed to high or medium level of radiation in an earlier published report. It was concluded that rs2735383G>C variation contributed to an increased risk of lung cancer possibly through miR-629 mediated targeting of NBS1 (Yang et al. 2012).

miR-629 was reported to be significantly higher in gastric cancer patients as compared to controls (Shin et al. 2015). It has been convincingly revealed that higher intracellular levels of miR-629-5p are noted in E6/E7 expressing cervical cancer cells (Honegger et al., 2015). Tripartite motif-containing 33 (TRIM33) is reportedly targeted by miR-629 that consequently inhibits IGΓβ/Smad signaling cascade (Jingushi et al., 2015).

Chapter 5 Discussion

The novelty of this study is that there is no work done on prostate cancer before. In this study we examined the *NBS1 gene* polymorphism in prostate cancer patients in Pakistani population. The results didn't show any significant association in prostate cancer patients. For rs13312986 A>G genotypes, AA was 75% in patients and 70% in controls. AG was 25% in patients and 30% in controls. GG was 0% in patients and none was detected in control. Allelic frequencies for A was 0.875 in patients and 0.85% in controls. Allelic frequencies for G were 0.125% in patients and 0.15% in controls. P. value was insignificant for rs13312986. A>G genotypes. For rs14448 F>C genotypes, TC was 71.6% in patients and 66.6% in controls. If was 28.3% in patients and 33.33% in controls. CC was not detected either in patients or controls. I allele was 0.64% in patients and 0.66% in controls. C. allele was 0.35% in patients and 0.33% in controls. P. value was insignificant for rs14448. I>C genotypes.

To summarize, our investigation on NBSI gene polymorphisms, this mutation did not show statistically significant association between prostate cancer patients and controls. Further studies are required to explore the detail mechanism, as miRNA regulation of NBS1 is not completely studied.

Chapter 5 Discussion

### Conclusion

Future studies surely will demystify detailed mechanisms, as miRNA regulation of NBS I is incompletely studied and exploration of these modulations will be helpful in getting a step closer to personalized medicine

### Future perspectives

Future studies must converge on investigation of mRNA levels of NBS1 from breast cancer patients and additional miRNAs, which possibly can modulate expression of NBS1 NBS1 is reported involved in regulation of DNA damage repair and future studies must converge on cell culture based studies using various phytochemicals to analyze changes in expression profiles of NBS1 and miR-629 Moreover, it needs to be studied in detail, if NBS1 is quantitatively controlled by other miRNAs. This information will be helpful in a broader and deeper analysis on miRNA regulation of DNA damage signaling network.

### REFERENCES

Allen J.E., and I.I-Deiry W.S., (2012) Regulation of the human TRAIL gene. Cancer Biology and Therapy. 13 p. 1143-1151

- Altuvia Y, Landgraf P, Lithwick G, Elefant N, Pfeffer S, and Aravin A, (2005) Clustering and conservation patterns of human microRNAs. *Nucleic Acids Research*, 33, p. 2697-2706
- Ambros V 2004 The functions of animal microRNAs Vature, 431, p. 350-355
- Andersen R.J., Mawji N.R., Wang J., Wang G., Haile S. and Myung J.K., (2010). Regression of castrate recurrent prostate cancer by a small-molecule inhibitor of the amino-terminus domain of the androgen receptor. *Cancer Cell*, 17, p. 535-546.
- Andriole G. Bruchovsky N, and Chung L W, (2004). Dihydrotestosterone and the prostate the scientific rationale for 5alpha-reductase inhibitors in the treatment of benign prostatic hyperplasia. *Journal of Urology*, 172, p. 1399-403.
- Attar R M, Takimoto C H, and Gottardis M M, (2009) Castration-resistant prostate cancer locking up the molecular escape routes. Clinical Cancer Research, 15, p. 3251-5
- Auffenberg G B. Helfand B T, and McVary K T, (2009) Established medical therapy for benign prostatic hyperplasia. *Urologic Clinics of North America*, 36, p. 443-459
- Ayala A.G., and Ro.J.Y., (2007). Prostatic intraepithelial neoplasia. recent advances. Archives of Pathology and Laboratory Medicine, 131, p. 1257-1266.
- Bartel D P (2004) MicroRNAs genomics, biogenesis, mechanism, and function Cell 116 p 281-297
- Bartel D.P., (2004) MicroRNAs genomics, biogenesis, mechanism, and function *Cell*, 116 p. 281-297
- Berezikov E. Guryev V., van de Belt J., Wienholds E., Plasterk R.H., and Cuppen L. (2005)

  Phylogenetic shadowing and computational identification of human microRNA genes

  Cell. 120 p. 21-24
- Bhatti S. Kozlov S., Farooqi A.A., Naqi A., Lavin M., and Khanna K.K. (2011). ATM protein kinase the linchpin of cellular defenses to stress. Cellular and Molecular Life Sciences 68, p. 2977-3006.
- Bhurgri Y, Kayani N, Pervez S, et al (2009) Incidence and trends of prostate cancer in Karachi South 1995–2002 Asian Pacific Journal of Cancer Prevention 10, p. 45-8

Bohnsack M.T. Czaplinski, K., and Gorlich D., (2004). Exportin 5 is a RanGTPdependent dsRNA-binding protein that mediates nuclear export of premiRNAs. *RNA*, 10, p. 185-191.

- Bostwick D.G. (1996) Prospective origins of prostate carcinoma. Prostatic intraepithelial neoplasia and atypical adenomatous hyperplasia. *Cancer*, 78, p. 330-336.
- Bostwick D.G. Burke H.B., and Djakiew D., (2004). Human prostate cancer risk factors. *Cancer* 101 p. 2371-2490.
- Bray I Lortet-lieulent J, Ferlay J, Forman D, and Auvinen A, (2010) Prostate cancer incidence and mortality trends in 37 European countries an overview European Journal of Cancer, 46, p. 3040-3052
- Bushman W (2009) Etiology epidemiology, and natural history of benign prostatic hyperplasia Urologic Clinics of North America, 36, p. 403-415
- Cai X / Hagedorn C H, and Cullen B R, (2004) Human microRNAs are processed from capped polyadenylated transcripts that can also function as mRNAs RV4 10 p 1957-1966
- Calin G A Dumitru C D, Shimizu M, Bichi R, Zupo S, Noch E, Aldler H Rattan S, Keating M, and Rai K, (2002) Frequent deletions and down-regulation of micro-RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia *Proceedings of the National Academy of Science U S A*, 99, p. 15524-15529
- Cardozo C.P., Michaud C., Ost M.C., Fliss A.E., Yang E., and Patterson C., (2003). C-terminal Hsp-interacting protein slows androgen receptor synthesis and reduces its rate of degradation. Archives of *Biochemistry* and *Biophysics*, 410, p. 134-140.
- Carney J.P. Maser R.S., Olivares H., Davis E.M., Le Beau M., and Yates III J.R., (1998). The hMrc11/hRad50 protein complex and Nijmegen breakage syndrome. linkage of double-strand break repair to the cellular DNA damage response. *Cell.*, 93, p. 477-486.
- Chan J Stampfer M, Ma J, et al (2001) Dairy products, calcium, and prostate cancer risk in the Physicians' Health Study American Journal of Clinical Nutrition, 74 p. 549-554
- Chen L. Lu M.H., Zhang D., Hao N.B., Fan Y.H., Wu Y.Y., Wang S.M. Xie R., Fang D.C. Zhang H. Hu C.J., and Yang S.M., (2014). miR-1207-5p and miR-1266 suppress gastric cancer growth and invasion by targeting telomerase reverse transcriptase. Cell Death Dis. 30, p. 1030-1034.
- Chen X M. (2005) Micro RNA biogenesis and function in plants. FEBS Letter, 579, 5923-5931.

Cheng A M. Byrom M W., Shelton J., and Ford L P., (2005a). Antisense inhibition of human miRNAs and indications for an involvement of miRNA in cell growth and apoptosis.

Nucleic Acids Research, 33, p. 1290-1297.

- Cheng L.C. Tavazoie M., and Doetsch F. (2005b) Stem cells from epigenetics to microRNAs.

  Neuron 46 p. 363-367
- Chodak G.W., Krane D.M., Puy L.A., Takeda H., Johnson K., and Chang C., (1992). Nuclear localization of androgen receptor in heterogeneous samples of normal, hyperplastic and neoplastic human prostate. *Journal of Urology*, 147, p. 798–803.
- Cole M.D. and McMahon S.B., (1999). The Myc oncoprotein a critical evaluation of transactivation and target gene regulation. *Oncogene*, 18, p. 2916-2924.
- Crawford E.D., and Petrylak D., (2010) Castration-resistant prostate cancer descriptive yet pejorative? *Journal of Clinical Oncology*, 28, p. 408
- D Amours D, and Jackson S P, (2002) The Mrel I complex at the crossroads of DNA repair and checkpoint signalling Nature Reviews Molecular and Cell Biology, 3 p 317-327
- Debes J.D., and Lindall D.J. (2004) Mechanisms of androgen refractory prostate cancer. The New Lingland Journal of Medicine, 351, p. 1488-1490
- Demura I, Shinohara N, and Tanaka M, (1996). The proportion of free to total prostate specific antigen a method of detecting prostate carcinoma. *Cancer*, 77, p. 1137-1143.
- Denlt A M, Tops B B J, Plasterk R H A. Ketting R F, and Hannon G J, 2004. Processing of primary microRNAs by the microprocessor complex. *Nature* 432, p. 231-235.
- Denmeade S R and Isaacs J T, (2002) A history of prostate cancer treatment. *Nature Reviews*Cancer 2 p 389-396
- Dohner H., Stilgenbauer S., Benner A., Leupolt E., Krober A., Bullinger L., Dohner K. Bentz M. and Lichter P., (2000). Genomic aberrations and survival in chronic lymphocytic leukemia. *New England Journal of Medicine*, 343, p. 1910-1916.
- I pstein J.I. (2010). An update of the Gleason grading system. *Journal of Urology*, 183 p. 433-440.
- Farooqi A A and Bhatti S, (2011) Getting personal with prostate cancer adding new pieces to an incomplete jigsaw puzzle. Urology International, 87, p. 127-133

I arooqi A A Attar R. Arslan B A., Romero M A., ul Haq M F., and Qadir M I., (2014) Recently emerging signaling landscape of ataxia-telangiectasia mutated (ATM) kinase Asian Pacific Journal of Cancer Prevention, 15, p. 6485-8

- Farooqi A.A., Fayyaz S., and Rashid S., (2012). Upon the tightrope in prostate cancer: two acrobats on the same tightrope to cross the finishline. Molecular Cell biochemistry, 364, p. 53-57.
- Farooqi A.A., Naqi A., Qureshi M.Z., Rana A., Khan A., Riaz A.M., Afzal S.M., Rasheed N. and Bhatti S. (2012). Prostate cancer is known by the companionship with ATM and miRNA it keeps craftsmen of translation have dual behaviour with tailors of life thread. Cell Biochemistry Functions, 30, p. 611-7.
- Farooqi A A, Qureshi M Z, Coskunpinar E, Naqvi S K, Yaylim I, and Ismail M, (2014) MiR-421 miR-155 and miR-650 emerging trends of regulation of cancer and apoptosis. Asian Pacific Journal of Cancer Prevention, 15, p. 1909-12
- Farooqi A A Waseem S, Ashraf M S, Iqbal M J, and Bhatti S, (2011) TRAIL and guardian angel of genome integrity ATM boards TRAIL blazer Journal of Cancer Research and Clinical Oncology, 137, p. 1283-7
- Harooqi A.A. Wu S.J., Chang Y.T., Tang J.Y., Li K.T., Ismail M., Liaw C.C., Li R.N., and Chang H.W. (2015). Activation and Inhibition of ATM by Phytochemicals. Awakening and Sleeping the Guardian Angel Naturally. Archivum immunologiae et therapiae experimentalis. 63, p. 357-366.
- Feldman B J, and Feldman D, (2001) The development of androgen-independent prostate cancer. Nature Reviews Cancer, 1, p. 34-45
- Ferlay J., Shin H.R., and Bray F., (2010) GLOBOCON 2008. Cancer incidence and mortality worldwide IARC, Cancer Base No. 10. Lyon France. *International Agency for Research on Cancer*
- Gatei M., Young D., Cerosaletti K. M., Desai-Mehta A., Spring K., and Kozlov S. (2000). ATM-dependent phosphorylation of nibrin in response to radiation exposure. *Nature Genetics* 25, p. 115-119.
- Gleason D.F. (1992). Histologic grading of prostate cancer: a perspective *Human Pathology*, 23 p. 273-279.
- Gottlieh I'M and Jackson S.P., (1993) The DNA-dependent protein kinase. Requirement for DNA ends and association with Ku antigen. *Cell*, 72, p. 131-142.

Gregory R.I., Chendrimada T.P., Cooch N., and Shiekhattar R., (2005). Human RISC couples microRNA biogenesis and posttranscriptional gene silencing. *Cell.*, 123, p. 631-640.

- Gregory R.I., Yan K.P., Amuthan G., Chendrimada T., Doratotaj B., Cooch N., and Shiekhattar R., (2004). The Microprocessor complex mediates the genesis of microRNAs. *Nature*, 432 p. 235-240.
- Griffiths-Jones S., Grocock R.J., van Dongen S., Bateman A., and Enright A.J., (2006). miRBase microRNA sequences, targets and gene nomenclature. *Nucleic Acids Research*, 34, p. 140-144.
- Grishok A., Pasquinelli A.E., Conte D., Li N., Parrish S., Ha I., Baillie D.L. Fire A., Ruvkun G. and Mello C.C., (2001). Genes and mechanisms related to RNA interference regulate expression of the small temporal RNAs that control C. elegans developmental timing. Cell. 106, p. 23-34.
- Gronberg H. (2003) Prostate cancer epidemiology Lancet, 361, p. 859-864
- Guo M Jiang Z. Zhang X. Lu D. Ha A D. Sun J. Du W., Wu Z., Hu L. Khadarian K. Shen J. and Lin Z. (2014) miR-656 inhibits glioma tumorigenesis through repression of BMPR1A Carcinogenesis, 35, p. 1698-706
- Han J J, Lee Y, Yeom K H, Kim Y K, Jin H, and Kim V N, (2004). The Drosha- DGCR8 complex in primary microRNA processing. *Genes and Development*, 18, p. 3016-3027.
- Hanahan D, and Weinberg R A, (2011) Hallmarks of cancer the next generation Cell 144 p 646-674
- Hao Y Zhao Y, Zhao X, He C, Pang X, and Wu T C, (2011) Improvement of prostate cancer detection by integrating the PSA test with miRNA expression profiling Cancer Investigation 29, p. 318-324
- Harutake S. Atsushi S. and Masaaki I., (2014). Feedback on baseline use of staging images is important to improve image overuse with newly diagnosed prostate cancer patients. Asian Pacific Journal of Cancer Prevention, 15, p. 1707-10.
- Hayashita Y Osada II, Tatematsu Y, Yamada H, Yanagisawa K, Iomida S, Yatabe Y Kawahara K, Sekido Y, and Takahashi Γ, (2005) A polycistronic microRNA cluster miR-17-92, is overexpressed in human lung cancers and enhances cell proliferation. Cancer Research, 65, p. 9628-9632

He I Thomson J.M., Hemann M.T., Hemando-Monge E., Mu D., Goodson S., Powers S., Cordon-Cardo C., Lowe S.W., Hannon G.J., and Hammond S.M. (2005b). A microRNA polycistron as a potential human oncogene. *Nature*, 435, p. 828-833.

- He I, Qi F, Jia I, Wang S, Song N, Guo L, Fu Y, and Luo Y, (2014). MicroRNA-542-3p inhibits tumour angiogenesis by targeting angiopoietin-2. *Journal of Pathology*, 232, p. 499-508.
- Helpap B G, Bostwick D G, and Montironi R, (1995) The significance of atypical adenomatous hyperplasia and prostatic intraepithelial neoplasia for the development of prostate carcinoma An update Virchows Archive, 426, p. 425-434
- Homma Y., Kawabe K., and Tsukamoto T., (1996). Estimate criteria for diagnosis and severity in benign prostatic hyperplasia. *International Journal of Urology*, 3, p. 261-266.
- Honegger A. Schilling D., Bastian S., Sponagel J., Kuryshev V., Sültmann H., Scheffner M., Hoppe-Seyler K., and Hoppe-Seyler F., (2015). Dependence of intracellular and exosomal microRNAs on viral E6/E7 oncogene expression in HPV-positive tumor cells *PLoS Pathology*. 11, p. e1004712.
- Hsing A, Chokkalingam A, Gao Y, et al (2002) Allium vegetables and risk of prostate cancer a population-based study *Journal of the National Cancer Institute*, 94, p. 1648-51
- Hsing A W and Devesa S S, (2001) Trends and patterns of prostate cancer what do they suggest? Epidemiologic Reviews, 23, p 3-13
- Huang W C, Chan S H, Jang T H, Chang J W, Ko Y C, Yen Γ C, Chiang S L, Chiang W I.
  Shieh I Y, Liao C T, Juang J L, Wang H C, Cheng A J, Lu Y C, and Wang L II.
  (2015) miRNA-491-5p and GIT1 serve as modulators and biomarkers for oral squamous cell carcinoma invasion and metastasis. Cancer Research, 74, 751-764
- Hutvagner G., McLachlan J., Pasquinelli A.E., Balint E., Tuschl T., and Zamore P.D. (2001) A cellular function for the RNA-interference enzyme Dicer in the maturation of the let-7 small temporal RNA. Science, 293, p. 834–838.
- Iorio M V., Ferracin M., Liu C G., Veronese A., Spizzo R., Sabbioni S., Magri F., Pedriali M., Fabbri M., Campiglio M., Menard S., Palazzo J P., Rosenberg A., Musiani P., Volinia S., Nenci I. Calin G A., Querzoli P., Negrini M., and Croce C M., (2005). MicroRNA gene expression deregulation in human breast cancer. Cancer Research, 65, p. 7065-7070.

Javidan J., Deitch A.D., Shi X.B., and de Vere White R.W., (2005). The androgen receptor and mechanisms for androgen independence in prostate cancer. *Cancer Imest.* 23, p. 520-8.

- Jemal A., Siegel R., Ward E., Hao Y., Xu J., and Thun M.J., (2009). Cancer statistics, 2009. 1

  Cancer Journal of Clincians, 59, p. 225-249.
- Jemal A, Thomas A, Murray T, and Thun M, (2002) Cancer statistics 4 Cancer Journal of Clineians, 52, p. 23-47
- Jingushi K. Ueda Y. Kitae K., Hase H., Egawa H., Ohshio I., Kawakami R., Kashiwagi Y. Isukada Y. Kobayashi T., Nakata W., Fujita K., Uemura M., Nonomura N., and Isujikawa K. (2015). miR-629 Fargets TRIM33 to Promote TGFβ/Smad Signaling and Metastatic Phenotypes in ccRCC. *Molecular Cancer Research*, 13, 565-574.
- Johnson S M. Grosshans H., Shingara J., Byrom M., Jarvis R., Cheng A., Labourier I. Reinert K.I. Brown D., and Slack F.J., (2005). RAS is regulated by the let-7 microRNA family. Cell. 120 p. 635-647
- Johnston R J, and Hobert O, (2003) A microRNA controlling left/right neuronal asymmetry in Caenorhabditis elegans. *Nature*, 426, p. 845-849
- Jung K., Lein M. Butz H., Stephan C., Loening S.A., and Keller T., (2006). New insights into the diagnostic accuracy of complexed and total prostate specific antigen using discordance analysis characteristics. *Journal of Urology*, 175, p. 1275-1280.
- Kang D I, Chung J I, and Ha H K, (2013) Korean prostate cancer patients have worse disease characteristics than their American counterparts Asian Pacific Journal of Cancer Prevention 14, p. 6913-7
- Ketting R Γ Fischer S E J, Bernstein F, Sijen T, Hannon G J, and Plasterk R II A, (2001)

  Diccr functions in RNA interference and in synthesis of small RNA involved in developmental timing in C elegans Genes and Development, 15 p 2654-2659
- Kim V.N. (2005) MicroRNA biogenesis coordinated cropping and dicing. Nature Reviews.

  Molecular Cell Biology, 6, p. 376-385
- Kronski F, Fiori M E, Barbieri O, Astigiano S, Mirisola V, Killian P H. Bruno A. Pagani A. Rovera F. Pfeffer U, Sommerhoff C P, Noonan D M, Nerlich A G. Fontana E, and Bachineier B E, (2014). miR181b is induced by the chemopreventive polyphenol curcumin and inhibits breast cancer metastasis via down-regulation of the inflammatory cytokines CXCLI and -2 Molecular Oncology, 8, p. 581-95.

Kutter C. and Svoboda P. (2008) miRNA, siRNA, piRNA Knowns of the unknown RNA Biologi. 5 p. 181-188

- Lagos-Quintana M. Rauhut R., Lendeckel W., and Tuschl T., (2001). Identification of novel gencs coding for small expressed RNAs. *Science*, 294, p. 853-858.
- I andthaler M. Yalein A., and Tuschl T., (2004). The human DiGeorge syndrome critical region gene 8 and its D. melanogaster homolog are required for miRNA biogenesis. *Current Biology*, 14, p. 2162-2167.
- Lee J.H. and Paull T.T., (2005) ATM activation by DNA double strand breaks through the Mre11-Rad50-Nbs1 complex Science, 308, p. 551-554
- Lee R.C., and Ambros V., (2001). An extensive class of small RNAs in Caenorhabditis elegans. Science, 294, p. 862-864.
- Lee Y Jeon K. Lee J.T. Kim S., and Kim V.N., (2002) MicroRNA maturation stepwise processing and subcellular localization. European Molecular Biology Organization Journal 21, p. 4663-4670.
- Fin ST Chang D, and Ying SY, (2005) Asymmetry of intronic pre-miRNA structures in functional RISC assembly *Gene*, 356, p. 32-38
- Lipski B.A. Garcia R.L., and Brawer M.K., (1996). Prostatic intraepithelial neoplasia significance and management. Seminars in Urologic Oncology, 14, p. 149-155.
- I und I., Guttinger S., Calado A., Dahlberg J.E., and Kutay U. (2004). Nuclear export of microRNA precursors. *Science*, 303, p. 95-98.
- Maser R.S., Zinkel R., and Petrini J.H., (2001). An alternative mode of translation permits production of a variant NBS1 protein from the common Nijmegen breakage syndrome allele. *Nature Genetics*, 27, p. 417-421.
- Matsuura S., Tauchi H., Nakamura A., Kondo N., Sakamoto S., Endo S., (1998). Positional cloning of the gene for Nijmegen breakage syndrome. *Nature Genetics*, 19, p. 179-181.
- Matthew I., Christopher A., and Haimane D., (2006). Admixture mapping identifies 8q24 as a prostate cancer risk locus in African-American men. *Proceedings of the National Academic of Sciences of the United States of America*, 103, p. 14068-73.
- Mazan-Mamczarz K, Zhao X F, Dai B, Steinhardt JJ, Peroutka RJ, Berk KI, Landon AL Sadowska M, Zhang Y, Lehrmann E, Becker KG, Shaknovich R Hiu Z and

Gartenhaus R B, (2014) Down-regulation of eIF4GII by miR-520c-3p represses diffuse large B cell lymphoma development *PLoS Genetics*, 30, p. 1-10

- Meister G, I andthaler M. Dorsett Y, and Tuschl T, (2004) Sequence-specific inhibition of microRNA- and siRNA-induced RNA sileneing RNA, 10, p. 544-550
- Miska E.A., Alvarez-Saavedra E., Townsend M., Yoshii A., Sestan N., Rakic P., Constantine-Paton M. and Horvitz H.R., (2004). Microarray analysis of microRNA expression in the developing mammalian brain. *Genome*, 5. p. R68.
- Moore M.A. Ariyaratne Y. and Badar F., (2010). Cancer epidemiology in South Asia past. present and future. Asian Pacific Journal of Cancer Prevention, 11, p. 49-6.
- Nath A Singh J Vendan S, et al (2012) Elevated level of prostate specific antigen among prostate cancer patients and high prevalence in the Gangetic Zone of Bihar, India Asian Pacific Journal of Cancer Prevention, 14, p. 63-8
- Nath A., Singh J.K., and Vendan S.E., (2012) Elevated level of prostate specific antigen among prostate cancer patients and high prevalence in the Gangetic zone of Bihar. India. Asian Pacific Journal of Cancer Prevention, 13, p. 221-3
- O'Donnell K.A. Wentzel E.A., Zeller K.I., Dang C.V., and Mendell J.T. (2005) c-Myc-regulated microRNAs modulate E2F1 expression. *Nature*, 435, p. 839-843
- Osborn A.J., I lledge S.J., and Zou L., (2002) Checking on the fork. The DNA-replication stress-response pathway. *Trends in Cell Biology*, 12, p. 509-516.
- Parkin D.M. Whelan S. J., Ferlay J., Teppo L., and Thomas D. B., (2003). Cancer Incidence in Five Continents. *International Agency for Research on Cancer* 8, p. 155.
- Pasquinelli A F., Reinhart B J., Slack F., Martindale M Q., Kuroda M I., Maller B., Hayward D C.
  Ball E E. Degnan B., Muller P., Spring J., Srinivasan A., Fishman M., Finnerty J., Corho
  J., Levine M., Leahy P., Davidson E., and Ruvkun G., (2000). Conservation of the sequence
  and temporal expression of let-7 heterochronic regulatory RNA. *Nature* 408 p. 86-89.
- Patel A R, and Klein E A, (2009) Risk factors for prostate cancer. *Vature clinical practice Leology*, 6, p. 87-95
- Pearson J.D. Luderer, Metter E.J., (1996). Longitudinal analysis of serial measurements of free and total PSA among men with and without prostatic cancer. *Journal of Urology*, 48, p. 4-9.

Peng X Guo W Liu I, Wang X, Tu X, and Xiong D, (2011) Identification of miRs-143 and -145 that is associated with bone metastasis of prostate cancer and involved in the regulation of EMT *PLoS One*, 6, p. 20341

- Potts J M (2001) The four categories of prostatitis a practical approach to treatment Cleveland Clinic Journal of Medicine, 68, p. 389-90, 392-3, 397
- Powell S.M., Christiaens V., Voulgaraki D., Waxman J., Claessens F., and Bevan C.I. (2004). Mechanisms of androgen receptor signalling via steroid receptor coactivator-1 in prostate. Endocrine Related Cancer, 11, p. 117-130.
- Quan II. Fong A, and Coster C, (2006) Variation in health services utilization among ethnic populations. Canadian Medical Association Journal, 174, p. 787-91
- Radmayr C, Lunacek A, Schwentner C, Oswald J, Klocker H, and Bartsch G, (2008) 5-alphareductase and the development of the human prostate *Indian Journal of Urology*, 24 p. 309-312
- Radmayr C Lunacek A. Schwentner C., Oswald J., Klocker H., and Bartsch G. (2012). 5-alphareductase and the development of the human prostate. Indian Journal of Urology. 24, p. 309-312.
- Raymundo I Rice KR Chen Y, (2010) Prostate cancer in Asian Americans incidence management and outcomes in an equal access healthcare system *Journal of the British*Association of Urological Surgeons, 107, p 1216-1222
- Reinhart B J Slack F J Basson M, Pasquinelli A E, Bettinger J C, and Rougvie A E (2000)

  The 21-nucleotide let-7 RNA regulates developmental timing in Caenorhabditis elegans

  Nature, 403, p. 901-906
- Rodriguez A, Griffiths-Jones S, Ashurst JL, and Bradley A, (2004) Identification of mammalian microRNA host genes and transcription units *Genome Research*, 14, p. 1902-1910
- Ross R K Fraument J F, and Schottenfeld D, (1996) Prostate Cancer Journal of Cancer Epidemiology and Prevention, 2, p 1180-1206
- Ruizeveld de Winter J.A., Trapman J., Vermey M., Mulder E., Zegers N.D., and van der Kwast I.H. (1991). Androgen receptor expression in human tissues: an immunohistochemical study. *Journal of Histochemistry* and *Cytochemistry*, 39, p. 927-936.

Sadi M V, Walsh P C, and Barrack E R, Immuno-histochemical study of androgen receptors in metastatic prostate cancer comparison of receptor content and response to hormonal therapy Cancer, 67, p. 3057-64

- Saraon P, Jarvi K, and Eleftherios P, (2011) Diamandis Molecular Alterations during Progression of Prostate Cancer to Androgen Independence Clinical Chemistry, 57 p 1366-1375
- Shiloh Y (1997) Ataxia-telangiectasia and the Nijmegen breakage syndrome related disorders but genes apart. *Annual Review of Genetics*, 31, p. 635-662
- Shin V Y, Ng E K, Chan V W, Kwong A, and Chu K M, (2015) A three-miRNA signature as promising non-invasive diagnostic marker for gastric cancer. *Molecular Cancer*, 14 p. 202-206
- Stanford J.L. Stephenson R.A., Coyle L.M., Cerhan J., Correa R. and Eley J.W., (1999). Prostate Cancer Trends 1973-1995. SEER Program, National Cancer Institute. VIII publication no. 99-4543.
- Stewart G.S., Maser R.S., and Stankovic T., (1999). The DNA double strand break repair gene hMREII is mutated in individuals with an ataxia-telangiectasia-like disorder. *Cell.*, 99 p. 577-587.
- lalaiezadeh A., Tabesh H., and Sattari A. (2013) Cancer incidence in southwest of Iran first report from Khuzestan population-based cancer registry, 2002-2009 Asian Pacific Journal of Cancer Prevention, 14, p. 7517-22
- Tanno B, Cesi V, Vitali R, Sesti F, Giuffrida M L, Mancini C, Calabretta B, and Raschella G (2005) Silencing of endogenous IGFBP-5 by micro RNA interference affects proliferation apoptosis and differentiation of neuroblastoma cells. *Cell Death and Differentiation*, 12, p 213-223
- Thomson J.M., Parker J., Perou C.M., and Hammond S.M., (2004). A custom microarray platform for analysis of microRNA gene expression. *Nature Methods*, 1, p. 47-53.
- Tomart Y and Jamore P.D., (2005). MicroRNA biogenesis. Drosha can't cut it without a partner. Current Biology, 15, p. R61-R64.
- Uziel I Lerenthal Y, Moyal E, Andegeko Y, Mittelman E. Shiloh Y. (2003) Requirement of the MRN complex for ATM activation by DNA damage. European Molecular Biology. Organization Journal, 22, p. 5612-5621.

Varon R., Vissinga C., Platzer M., Cerosaletti K.M., Chrzanowska K.H., and Saar K. (1998)

- Yu I. Li J. Yan M., Liu L., Lin H., Zhao F., Sun L., Zhang Y., Cui Y., Zhang F., Li J., He X. and Yao M. (2015) MicroRNA-193a-3p and -5p suppress the metastasis of human non-References small-cell lung cancer by downregulating the ERBB4/PJK3R3/m1OR/S6K2 signaling pathway Oncogene, 34, p. 413-423
- Yuan Z., Zhang X., Sengupta N., Lane W.S., and Seto E., (2007) SIRT1 regulates the function of the Nijmegen breakage syndrome protein Molecular Cell, 27, p. 149-162
- Zeng Y Cai X, and Cullen BR, (2005) Use of RNA polymerase II to transcribe artificial
- Zhang B Pan A, George P, Todd C, Anderson A, (2007) Computational identification of microRNAs and their targets. Computational Biology And Chemistry, 30, p. 395-407
- /hi/, Shi-Xin L. and Tian Z, (2014) Abiraterone for treatment of metastatic castration-resistant prostate cancer a systematic review and meta-analysis Asian Pacific Journal of Cancer Prevention 15, p 1313-20
- Zhu J. Petersen S., Tessarollo L., and Nussenzweig A., (2001). Targeted disruption of the Nijmegen breakage syndrome gene NBSI leads to early embryonic lethality in mice Current Biology, 11, p 105-109
- Zou I, and Elledge SJ, (2003) Sensing DNA damage through ATRIP recognition of RPAssDNA complexes Science, 300, p 1542-8

Varon R, Vissinga C, Platzer M, Cerosaletti K M, Chrzanowska K H, and Saar K, (1998)
Nibrin, a novel DNA double-strand break repair protein, is mutated in Nijmegen breakage syndrome Cell, 93, p. 467-476

- Volinia S., Calin G.A., Liu C.G., Ambs S., Cimmino A., Petrocca F., Visone R., Iorio M., Roldo C., Ferracin M., Prucitt R.L., Yanaihara N., Lanza G., Scarpa A., Vecchione A., Negrini M., Harris C.C., and Croce C.M., (2006). A microRNA expression signature of human solid tumors defines cancer gene targets. Proceedings of the National Academy of Science U.S. 4, 103, p. 2257-2261.
- Voorhoeve P.M. le Sage C., Schrier M., Gillis A.J.M., Stoop H., Nagel R., Liu Y.P., van Duijse J. Drost J. and Griekspoor A., (2006). A genetic screen implicates miRNA-372 and miRNA-373 as oncogenes in testicular germ cell tumors. *Cell.*, 124, p. 1169-1181.
- Wan G Mathur R, Hu X, Zhang X, and Lu X, (2011) miRNA response to DNA damage Trends in Biochemical Sciences, 36, p. 478-484
- Wasserman N F, (2006) Benign prostatic hyperplasia a review and ultrasound classification Radiologic Clinics of North America, 44, p. 689-710
- Wolf A M Wender R C and Etzioni R B, (2010) American cancer society guideline for the early detection of prostate cancer update 2010 A Cancer Journal of Clincians, 60, p. 70-98
- Xiao Y, and Weaver DT, (1997) Conditional gene targeted deletion by Cre recombinase demonstrates the requirement for the double-strand break repair Mre11 protein in murine embryonic stem cells. *Nucleic Acids Research*, 25, p. 2985-2991
- Yang L., Li Y. Cheng M., Huang D., Zheng J., Liu B., Ling X., Li Q., Zhang X. Ji W., Zhou Y. and Lu J., (2012). A functional polymorphism at microRNA-629-binding site in the 3'-untranslated region of NBS1 gene confers an increased risk of lung cancer in Southern and Eastern Chinese population. Carcinogenesis, 33, p. 338-47.
- Yi R, Qin Y, Macara I G, and Cullen B R, (2003) Exportin-5 mediates the nuclear export of pre-microRNAs and short hairpin RNAs. Genes and Development, 17, p. 3011-3016
- Yin M. Ren X. Zhang X., Luo Y., Wang G., Huang K., Feng S., Bao X. Huang K., He X., Liang P., Wang Z., Tang H., He J., and Zhang B., (2015). Selective killing of lung cancer cells by miRNA-506 molecule through inhibiting NF-κB p65 to evoke reactive oxygen species generation and p53 activation. *Oncogene*, 34, p. 691-703

- Yu F Li J Yan M, Liu L Lin H, Zhao F, Sun L, Zhang Y, Cui Y, Zhang F, Li J, He X and Yao M (2015) MicroRNA-193a-3p and -5p suppress the metastasis of human non-small-cell lung cancer by downregulating the ERBB4/PIK3R3/m FOR/S6K2 signaling pathway Oncogene, 34, p. 413-423
- Yuan Z., Zhang X., Sengupta N., Lane W.S. and Seto E., (2007). SIRT I regulates the function of the Nijmegen breakage syndrome protein. *Molecular Cell.*, 27, p. 149-162.
- /eng Y, Cai X and Cullen BR, (2005) Use of RNA polymerase II to transcribe artificial microRNAs Methods in Enzymology, 392, p. 371-380
- /hang B Pan X, George P Todd C, Anderson A, (2007) Computational identification of microRNAs and their targets. Computational Biology And Chemistry, 30 p 395-407
- Zhi Z, Shi-Xin L, and Tian Z, (2014) Abiraterone for treatment of metastatic castration-resistant prostate cancer a systematic review and meta-analysis Asian Pacific Journal of Cancer Prevention, 15, p. 1313-20
- /hu J Petersen S. Fessarollo L., and Nussenzweig A., (2001) Targeted disruption of the Nijmegen breakage syndrome gene NBS1 leads to early embryonic lethality in mice Current Biology, 11, p. 105-109
- Jou L, and Elledge SJ, (2003) Sensing DNA damage through ATRIP recognition of RPAssDNA complexes. Science, 300, p. 1542-8